基石药业(02616.HK)联合疗法获临床试验批准
基石药业(02616.HK)公布,公司治疗局部晚期或转移性肝细胞癌的CS1001联合BLU-554疗法在中国获临床试验批准。试验旨在评价此联合疗法在晚期肝细胞癌中的安全性、耐受性、药代动力学及药效学特徵和抗肿瘤疗效。
CS1001是基石药业自主研发的抗PD-L1单抗,也是公司三款肿瘤免疫治疗骨干产品之一。BLU-554则由公司合作夥伴Blueprint开发,是一款强效高选择性的成纤维细胞生长因数受体-4抑制剂。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.